Utilizing Circulating Tumor Cell Changes and Tumor Pathology to Predict Early Relapse in Resectable Non-Small Cell Lung Cancer Patients: A Prospective Clinical Feasibility Trial

What this Trial Is About

This research aims to improve the identification of patients with resectable non-small cell lung cancer who are at risk of early relapse after tumor removal. Early relapse significantly affects survival, yet current imaging and screening methods cannot reliably predict which patients will experience it. By studying circulating tumor cells (CTCs) and tumor pathology, the trial seeks to better select patients for adjuvant therapy to reduce early relapse. The study uses a combined relapse prediction model that tracks changes in circulating tumor cells around the time of surgery and examines tumor pathology. Patients identified as high risk based on these factors may receive cisplatin-based chemotherapy as adjuvant therapy following surgery. The study follows recommended guidelines for adjuvant treatment and observes patients over time to assess outcomes. Participants will undergo blood sampling to monitor circulating tumor cells and regular clinical surveillance at three-month intervals. Researchers will measure the accuracy of the relapse prediction model and early relapse rates, as well as overall survival, through ongoing follow-up. The study monitors participants from surgery through treatment and regular check-ups until the study concludes in 2028.

Combined Relapse Prediction Model for Resectable Non-Small Cell Patients - a Prospective Clinical Feasibility Trial